GERN
Price
$1.29
Change
+$0.02 (+1.57%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
808.89M
21 days until earnings call
IDYA
Price
$22.12
Change
-$0.03 (-0.14%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
1.94B
26 days until earnings call
Interact to see
Advertisement

GERN vs IDYA

Header iconGERN vs IDYA Comparison
Open Charts GERN vs IDYABanner chart's image
Geron
Price$1.29
Change+$0.02 (+1.57%)
Volume$79.21K
Capitalization808.89M
IDEAYA Biosciences
Price$22.12
Change-$0.03 (-0.14%)
Volume$34.75K
Capitalization1.94B
GERN vs IDYA Comparison Chart in %
Loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GERN vs. IDYA commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (GERN: $1.27 vs. IDYA: $22.15)
Brand notoriety: GERN and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 77% vs. IDYA: 55%
Market capitalization -- GERN: $808.89M vs. IDYA: $1.94B
GERN [@Biotechnology] is valued at $808.89M. IDYA’s [@Biotechnology] market capitalization is $1.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $300.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • GERN’s TA Score: 3 bullish, 6 bearish.
  • IDYA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than GERN.

Price Growth

GERN (@Biotechnology) experienced а -11.81% price change this week, while IDYA (@Biotechnology) price change was -3.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.69%, and the average quarterly price growth was +40.92%.

Reported Earning Dates

GERN is expected to report earnings on Nov 06, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.94B) has a higher market cap than GERN($809M). IDYA YTD gains are higher at: -13.813 vs. GERN (-64.124). GERN has higher annual earnings (EBITDA): -114.49M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. GERN (397M). IDYA has less debt than GERN: IDYA (26M) vs GERN (122M). GERN has higher revenues than IDYA: GERN (116M) vs IDYA (7M).
GERNIDYAGERN / IDYA
Capitalization809M1.94B42%
EBITDA-114.49M-356.46M32%
Gain YTD-64.124-13.813464%
P/E RatioN/AN/A-
Revenue116M7M1,657%
Total Cash397M693M57%
Total Debt122M26M469%
FUNDAMENTALS RATINGS
GERN vs IDYA: Fundamental Ratings
GERN
IDYA
OUTLOOK RATING
1..100
5659
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
10078
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
6558
P/E GROWTH RATING
1..100
71100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (62) in the null industry is in the same range as GERN (92) in the Biotechnology industry. This means that IDYA’s stock grew similarly to GERN’s over the last 12 months.

IDYA's Profit vs Risk Rating (78) in the null industry is in the same range as GERN (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to GERN’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as GERN (97) in the Biotechnology industry. This means that IDYA’s stock grew similarly to GERN’s over the last 12 months.

IDYA's Price Growth Rating (58) in the null industry is in the same range as GERN (65) in the Biotechnology industry. This means that IDYA’s stock grew similarly to GERN’s over the last 12 months.

GERN's P/E Growth Rating (71) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that GERN’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERNIDYA
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
74%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TMDIX18.36N/A
N/A
AMG TimesSquare Mid Cap Growth Z
MSGLX12.09N/A
N/A
MassMutual Small Cap Gr Eq Adm
HUMDX15.81N/A
N/A
Huber Mid Cap Value Inv
SHSKX65.79N/A
N/A
BlackRock Health Sciences Opps K
STSCX40.19N/A
N/A
Sterling Capital SmCp Val Instl

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
+0.79%
SER - GERN
66%
Loosely correlated
-2.83%
LIANY - GERN
53%
Loosely correlated
+22.22%
VCYT - GERN
44%
Loosely correlated
-5.55%
DAWN - GERN
41%
Loosely correlated
+0.76%
IDYA - GERN
38%
Loosely correlated
+3.36%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+3.36%
IMNM - IDYA
60%
Loosely correlated
+15.12%
CGON - IDYA
60%
Loosely correlated
+4.53%
NRIX - IDYA
59%
Loosely correlated
+2.22%
CRNX - IDYA
59%
Loosely correlated
+0.22%
XENE - IDYA
58%
Loosely correlated
+0.44%
More